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Ovarian cancer is not an entity 
but a group of diseases. Studies of 
the result of treatment must be 
based on homogenous groups of 
tumors and not on mixtures of his-
tologically and biologically differ-
ent tumor types. Furthermore, 
there still exists a considerable de-
gree of confusion as to which tu-
mors should be considered true 
carcinomas. Experience has shown 
that between obviously benign and 
obviously malignant neoplasms 
there exists a group of well-differ-
entiated tumors that, in their clini-
cal behavior, resemble true carci-
nomas, inasmuch as they give rise 
to implantation metastases and 
ascites and cause the death of the 
patient, but yet have quite a dif-
ferent course. The lack of generally 
accepted definitions of the various 
histological forms has resulted in 
the extreme differences in long-
term results given by various au-
thors. The importance of elaborat-
ing a standardized, internationally 
accepted classification of ovarian 
tumors so that the results of dif-
ferent clinics may be accurately 
compared is obvious. The Interna-
tional Federation of Gynecology 
and Obstetrics has adopted a histo-
pathologic classification of ovarian 
tumors related to the Miillerian 
epithelium. They consist of the 
serous, mucinous, and endometrioid 
types. The so-called endometrioid 
carcinomas resemble adenocarci-
noma of the endometrium. In gen-
eral they are well differentiated, 
while the majority o~ serous carci-
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nomas are more or less undiffer-
entiated. 
Table 1 gives the histologic classi-
fication of the primary epithelial 
tumors. Figure 1 presents the sur-
vival rates of serous cystomas. 
From the figures given it is obvious 
that well-differentiated tumors of 
low potential malignancy ought to 
be separated from true carcinomas. 
We all share the opinion that, in 
general, the prognosis is poor. 
Ovarian carcinomas are frequently 
not discovered until the growth has 
extended to surrounding organs or 
has given rise to metastases. The 
treatment becomes progressively 
less effective with increasing ana-
tomic extent of the disease. 
The necessity of an early diag-
nosis is obvious. Laparoscopy has 
proved to be of value in many cases 
and can promote an early diag-
nosis. Hysterosalpingography, ar-
teriography, and needle biopsies 
through the vagina or the rectum 
may help in this respect. The rou-
tine use of cul de sac aspiration 
may result in the detection of oc-
cult carcinomas as brilliantly dem-
onstrated by the Grahams ( 1964) . 
Sometimes a laparotomy is neces-
sary to permit a final diagnosis. 
Explorative laparotomy facil-
itates the outlining of the borders 
of growth by direct inspection and 
palpation, and should be routinely 
carried out whenever there is the 
slightest suspicion of an ovarian tu-
mor. Some years ago gynecologists 
considered it appropriate to apply 
conservative treatment in patients 
with physiologic enlargements or 
cysts of the ovary. It is often dif-
ficult to decide whether an enlarge-
ment of the ovary is physiologic or 
neoplastic. Since today laparotomy 
is quite a safe procedure, it is wise 
to perform this operation on the 
slightest suspicion of an ovarian 
neoplasm. 
Surgery 
During laparotomy the surgeon 
should outline in detail the exten-
sion of the growth and take several, 
rather large, biopsies from areas 
that seem to be suspicious. The es-
tablishment of the anatomical ex-
tent of the carcinoma is important 
in planning further therapy. Experi-
ence has proved that serous carci-
nomas grow fast and give rise to 
extensive metastases at an early 
stage, whereas mucinous tumors 
are confined to the ovary for a long 
time, and endometrioid carcinomas 
tend to be multicentric, but remain 
to the true pelvis for a long time. 
Metastases above the pelvis were 
diagnosed in 147 of 276 cases 
(53.3 % ) of serous carcinoma, in 
9 of 51 cases ( 17.6% ) of mucinous 
carcinoma, and in 29 of 168 cases 
(17 .2 % ) of endometrioid carci-
noma. The carcinoma was limited 
to the ovaries and uterus in 55 of 
276 cases (19.9 % ) of serous neo-
plasm, in 30 of 51 cases (58.8%) 
of mucinous neoplasm, and in 58 
or 168 cases ( 34.5 % ) of endome-
trioid neoplasm. 
It should be stressed, though, 
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TABLE 1 
Histologic Classification of Common Primary Epithelial Tumors of the Ovary 
I. Serous cystomas 
a. Serous benign cystadenoma. 
b. Serous cystadenomas with proliferating activity of the epithelial cells 
and nuclear abnormalities, but with no infiltrative destructive growth 
(low potential malignancy). 
c. Serous cystadenocarcinomas. 
II. Mucinous cystomas 
a. Mucinous benign cystadenomas. 
b. Mucinous cystadenoma~ with proliferating activity of epithelial cells 
and nuclear abnormalities, but with no infiltrative destructive growth 
(low potential malignancy). 
c. Mucinous cystadenocarcinomas. 
III. Endometrioid tumors (similar to adenocarcinomas in the endometrium) 
a. Endometrioid benign cysts. 
b. Endometrioid tumors with proliferating activity of the epithelial cells 
and nuclear abnormalities, but with no infiltrative destructive growth 
(low potential malignancy). 
c. Endometrioid adenocarcinomas. 
IV. Concomitant carcinoma, unclassified carcinoma 
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Fig. 1-Ten-year survival rates of cystomas (375 cases). 
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that the excision of an ovarian car-
cinoma should be performed to the 
greatest possible extent. Every ef-
fort should be made to keep the 
capsula intact. Even if the tumor 
is unilateral, it is advisable to re-
move the opposite ovary. In young 
patients and in those who want to 
have children, a unilateral oopho-
rectomy may be considered. If, 
however, the tumor is a serous type, 
a relaparotomy is indicated, as the 
normal ovary may frequently har-
bor microscopic metastases. 
An extended operation, for in-
stance with resection of the small 
or large bowel, is indicated at least 
in carcinomas that are likely to be 
mucinous, as at a late stage these 
neoplasms give rise to metastases 
and evidently are radioresistant. 
Whether this management is advis-
able in serous and endometrioid 
carcinomas is doubtful. It is our 
experience that extensive surgery 
in such neoplasms smears cancer 
cells over the peritoneum, opens 
lymph and blood vessels, and favors 
implantations and metastases. The 
removal of serous or endometrioid 
carcinomas fixed to surrounding 
tissue by firm adhesions destroys 
the defensive reaction of the body. 
Recurrences appear rapidly and do 
not, as a rule, respond to radiation, 
nor to any other therapy. Although 
we cannot prove so at present, it 
seems logical to try radiotherapy 
prior to excisional surgery. Conse-
quently, the laparotomy should be 
restricted to an exploratory opera-
tion. Biopsies should be taken and 
irradiation administered to the area 
outlined on surgery. It is not ap-
propriate to exceed a dose of 4,000 
rad in five weeks. Re-operation 
should be carried out 10 to 14 days 
after completion of radiotherapy . 
Most gynecologists prefer to per-
form a panhysterectomy in addi-
tion to oophorectomy because of 
possible transtubal metastases to 
the endometrium. I am not con-
vinced that, as a rule, a hysterec-
tomy is to be recommended. Intrau-
terine application of radioactive 
sources renders a treatment to the 
cul de sac possible. Metastases or 
pelvic recurrences appear first and 
foremost in the cul de sac. A heavy 
dose of radiation can be given to 
this area if external irradiation is 
combined with intrauterine radium. 
Insertion of radium into the vagina 
is not valuable. 
Resection of the omentum has 
been recommended whenever any 
surgical procedure for ovarian can-
cer is performed. Metastases to the 
omentum are diagnosed in many 
cases. At Radiumhemmet we have 
not been convinced that prophylac-
tic omentectomy is valuable and 
will improve the outcome. In cases 
of metastases to the omentum, a 
resection lessens the degree of 
ascites accumulation. Yet, a stipula-
tion is that a cutting of the omen-
tum is not made through carcino-
matous tissue. 
Application of Radioactive 
Sources 
lntraperitoneal examination or 
removal of an ovarian carcinoma 
will spread cancer cells to various 
parts of the peritoneal cavity. It 
is likely that such superficial peri-
toneal transplants are eradicated by 
the intraperitoneal application of 
colloidal radioactive sources. Mill-
ier ( 1959) has for years applied 
radioactive gold intraperitoneally 
after surgery. His results support 
the value of this method. Radi-
umhemmet, and many others, has 
substituted chemotherapeutic agents 
such as Nitrogen mustard, Thio-
TEP A, Cytoxan, etc., for the iso-
tope. The effect of intra-abdominal 
application of isotopes or of chemi-
cal drugs has so far not been as 
satisfactory as we had expected. 
Radiation Therapy 
The survival rate in true ovarian 
carcinoma is dependent on the ana-
tomical extent of the carcinoma. 
Serous carcinomas have a tendency 
to give metastases above the pelvis 
and distant metastases, while en-
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dometrioid carcinomas are often 
limited to the pelvis. Radiation 
should start as soon as possible 
after surgery if laparotomy and fur-
ther examination have proved that 
the cancer is incompletely removed, 
but yet is limited to the true pelvis. 
Many authors have reported an in-
crease of survivors if radiotherapy 
is given postoperatively. At Radi-
umhemmet a five-year survival rate 
of 1 7 .1 % has been reached in 3 5 
cases of serous, and 50.0% in 24 
cases of endometrioid carcinoma 
with non-resectable metastases in 
the true pelvis. The correspond-
ing three-year survival rates are 
23.6% in 55 cases of serous, and 
50.0% in 50 cases of endometrioid 
carcinoma. These figures suggest 
that endometrioid carcinomas do 
respond better to irradiation than 
serous ones. 
In these patients conventional x-
ray therapy with a half value layer 
of 1 to 2 mm Cu has been adminis-
tered through two large opposing 
fields in addition to intrauterine ap-
plication of radium. 
Irradiation of the pelvis can be 
achieved more efficiently with su-
pervoltage radiation than with con-
ventional roentgen therapy. As a 
consequence of our experience that 
endometrioid carcinomas possibly 
respond better to irradiation than 
serous carcinomas do, cases of 
serous and endometrioid neoplasms 
with extension to tissues in the true 
pelvis are at present receiving co-
balt beam therapy with a dose of 
4,500 to 5,000 rad to the midpelvis 
over a period of six to seven weeks. 
Two large opposing portals or a 
three-field technique are being used 
in these cases. The latter method is 
chosen for cases in which the ex-
tent of the carcinoma is outlined in 
detail, and, thus, a reduced dose 
can be given to the bladder, rec-
tum, and small bowel partly with 
the use of wedge-filters. The radia-
tion is delivered through one large 
anterior and two lateral fields. 
The radiation technique men-
tioned is applied also in cases of 
true ovarian carcinoma in which 
the tumor was removed completely. 
However, in such cases the dose 
from external radiation is decreased 
to about 3,000 rad. 
The radiation therapy described 
has been used at Radiumhemmet 
since 1964. For the time being it is 
impossible to draw any conclusions, 
but we do believe that results will 
be improved. 
I have mentioned previously that 
at Radiumhemmet radiotherapy 
was also given to cases of true 
ovarian carcinoma with metastases 
above the pelvis. Only two of 114 
such patients with serous carcinoma 
are living symptom-free at five 
years. The corresponding number 
of endometrioid carcinoma is four 
of 24. It is likely that radiotherapy 
will bring about a palliation in ad-
vanced cases of true ovarian carci-
nomas, but it is questionable 
whether the five-year survival in six 
of 138 cases can be attributed to 
the radiation delivered in rather 
small doses. Possibly, the survival 
is due to a slow growth of the dis-
ease. However, we have tried re-
cently to deliver dosages of 3,500 
to 5,000 rad to the total abdominal 
cavity in selected cases of ovarian 
carcinoma with extensive metasta-
ses over the entire peritoneal cavity. 
The radiation has been applied 
through six fields with central doses 
of 700 rad over a period of five 
days. Remarkably enough the pa-
tients have withstood the radiation 
satisfactorily. Their general condi-
tion has improved, the ascites has 
disappeared, and sometimes the tu-
mor has decreased considerably in 
size. However, it is yet doubtful 
whether the survival in cases of 
serous carcinoma has been pro-
longed. Such a radiation as men-
tioned may be tried as an experi-
ment but should not be applied 
routinely. 
Another attempt to increase the 
dose to the entire abdomen has 
been made at the M. D . Anderson 
Hospital, Houston. Megavoltage ir-
radiation was given through multi-
ple narrow horizontal strips. Ac-
tually, this is a modification of the 
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overlapping x-ray strip technique 
recommended by Patterson for ra-
diation of the trunk. The realiza-
tion of this radiation technique is 
difficult in cases of carcinoma with 
ascites. 
Table 2 gives the survivals in 
555 cases of ovarian carcinoma 
treated five years ago or earlier. 
Chemotherapy 
Great attention has been drawn 
to radiomimetic substances in the 
hope that they may delay the 
growth of the carcinoma. Experi-
ence has shown that the use of 
compounds similar to Nitrogen 
mustard have been a success in 
causing regression of ovarian car-
cinoma. Since the publications by 
Bateman (1955; Bateman and Win-
ship, 1956) and others, Thio-TEPA 
has been reported to be useful in 
the management of ovarian carci-
nomas, but Chlorambucil, E-39, 
Endoxan, Sarcolysin, Hemisulphur 
mustard, etc., have also produced 
good palliation in many cases. At 
Radiumhemmet we have chosen 
Thio-TEPA in the treatment of 
ovarian carcinoma and have used it 
exclusively or in combination with 
irradiation. 
The intracavitary application of 
cytotoxic agents has also been used 
to a large extent at Radiumhemmet. 
For years we nourished the hope 
that intraperitoneal instillation of 
Nitrogen mustard or similar drugs 
would lead to palliative results simi-
lar to those achieved by colloidal 
TABLE 2 
radioactive substances. Unfortun-
ately, experience has shown that 
this does not hold valid for ascites. 
Nor does prophylactic installation 
of Thio-TEP A into the peritoneal 
cavity after laparotomy seem to be 
valuable, whether it is administered 
continuously or by injection. 
From 1960 through 1962, an in-
vestigation was carried out to ex-
plore whether chemotherapy given 
in addition to radiation would im-
prove survival rates (Kottmeier, 
1967). Thio-TEPA was given in-
travenously in moderate doses in 
32 cases in which the ovarian car-
cinoma had been incompletely re-
moved, but no extrapelvic metasta-
ses were traced. The follow-up of 
these cases has not revealed any 
benefit attributable to chemother-
apy. 
With the purpose of studying the 
effect on cases of ovarian carci-
noma that were either completely 
inoperable or had given rise to 
several unresectable metastases 
above the pelvis, Thio-TEPA was 
injected intravenously in 131 pa-
tients, whereas 88 patients received 
only radiation. The aim was to 
maintain a combined therapy until 
depression of the bone marrow had 
appeared. In 42 of the 131 patients, 
therapy was given until the leuco-
cytes and thrombocytes were de-
pressed to very low levels. Table 3 
presents the distribution of the cases 
in regard to the histopathological 
type of the growth. The serous car-
cinomas amount to 38% in the ir-
radiated group and 56% in that 
Five-Year Survival of Patients with Ovarian Carcinomas 
No. Patients Surviving After: 
Type of No. Patients 
Carcinoma Treated 1 yr. 2 yrs. 3 yrs. 4 yrs. 5 yrs. 
Serous 276 149 95 68 48 41 
Mucinous 51 39 35 33 32 32 
Endometrioid 168 138 115 106 102 93 
Unclassified 60 29 18 17 14 13 
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which had received combined ther-
apy. 
From the study (Fig. 2, table 
4) it is obvious that combined 
treatment has proved to be effec-
tive in producing a prolonged sur-
vival and a noticeable subjective 
improvement in many cases of ex-
tensive ovarian carcinoma in which 
chemotherapy was given in large 
doses. 
As a consequence of this trial we 
give Thio-TEP A intravenously to 
patients with extensive ovarian car-
cinoma, especially if the growth is 
the serous type. It is important to 
continue chemotherapy until a de-
pression of the bone marrow oc-
curs. It is, therefore, not sufficient 
to keep the blood count under close 
observation. Repeated bone mar-
row biopsies must be made during 
the course of therapy, especially as 
occasionally the blood count does 
not correspond to the cellular pat-
tern of the bone marrow taken 
from the sternum. 
Thio-TEP A is given intraven-
ously with a dose of 10 mg daily or 
every second day. The initial dose 
varies considerably. The patient is 
kept under close observation also 
for several weeks after the comple-
tion of therapy, as a severe late de-
pression of the leucocytes and 
platelets may sometimes occur two 
to four weeks later. The patients 
have a depressed immunity to in-
fections. The treatment involves a 
risk of aplastic marrow or septicae-
mia. Five patients have died as a 
sequel of therapy. 
For the time being we do not 
know whether a combined treat-
ment of irradiation and chemother-
apy is preferable to chemotherapy 
alone in cases of true ovarian car-
cinoma with extension above the 
pelvis. We suppose that a com-
bined treatment is appropriate in 
cases of endometrioid carcinoma. 
In this respect I call attention to 
the fact that therapy should begin 
with radiation, and chemotherapy 
should be given subsequently. In-
vestigations carried out have shown 
that apparent hyperplasia of the 
cellular pattern in marrow from 
the sternum occurs during the first 
two weeks of irradiation. 
Recent observations support the 
opinion that chemotherapy alone 
is preferable to combined treat-
ment in cases of extensive serous 
and mucinous carcinomas. Pro-
vided initial treatment has yielded 
a good effect, further chemother-
apy with Thio-TEP A or Endoxan 
in moderate doses should be given, 
under observation, though, of the 
blood count. In our experience, 
however, the platelets will never 
return to normal level. In addition 
blood transfusions and testosterone 
in large doses should be given. 
Repeated Surgery 
One important question remains: 
Should surgery be carried out in 
cases of extensive ovarian carci-
noma that, on initial examination 
and/ or laparotomy, were consid-
ered completely inoperable and that 
had responded satisfactorily to 
treatment applied? Radiumhemmet 
has advocated for years that in 
these cases a laparotomy should be 
made with removal of as much of 
the disease as is possible. In the 
years 1958 through 1962, this was 
carried out in 45 cases of serous 
carcinoma, in eight cases of en-
dometrioid carcinoma, and in 10 
cases of unclassified true carci-
noma. Six, two, and three patients 
respectively have survived three 
years after initial therapy. Five pa-
tients are living at five years; only 
one survived of the 45 patients with 
serous carcinoma. However, in 24 
of the 63 patients operated upon, 
the disease exploded following sur-
gery. As a consequence of these 
poor results, we only occasionally 
advocate surgery in cases of ex-
tensive ovarian carcinoma that 
from the beginning are considered 
completely inoperable. However, 
we do agree with Rutledge that 
modern therapy with application 
of chemical drugs in repeated se-

















Histopathological Distribution of 219 Cases of Inoperable 
Ovarian Carcinoma. Results of Treatment with Irradiation 




Pathologic Type No. Cases No. Cases 
Serous 33 (38%) 74 (56%) 
Mucinous 2 1 
Endometrioid 15 (17%) 18 (14%) 
Unclassified 14 (16%) 22 (17%) 
No microscopic 
examination 24 (27%) 16 (12%) 
Total 88 131 
INOPERABLE OVARIAN CARCINOMAS 1960-1962 
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Fig. 2-Inoperable ovarian carcinomas, 1960-1962. A randomized study to 
establish the value of chemotherapy as an adjunct to irradiation. 
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TABLE 4 
Sustained Palliation in 219 Cases of 






No. Cases Effect 
17 None 
116 Good 
Ovarian Carcinoma of Low 
Potential Malignancy 
Regarding 121 cases of so-called 
" questionable" carcinomas treated 
five years ago and 15 6 cases treated 
at least three years ago, I have not 
much to add. In cases of unilateral 
growth, surgery with preservation 
.of the normal ovary may be ade-
quate therapy. Radical excision is 
important especially in cases of 
mucinous tumor, as fragments of 
neoplastic tissue left behind may 
lead to pseudomyxoma peritonaei. 
Radiotherapy with doses not ex-
·ceeding 3,000 rad is expedient in 
all other cases in which the tumor 
.could not be completely removed. 
Relaparotomy is indicated in cases 
initially considered inoperable 
which improved after radiation 
therapy. A five-year survival rate 
of 79.6% has been attained in 49 
cases of low potential carcinomas 
with metastases. The corresponding 
three-year survival rate in 67 cases 
is 85.1 % . 
Summary 
I have made it my task with this 
paper to outline principles for the 
treatment of ovarian carcinoma. 
Emphasis has been laid on pathol-
ogy and on anatomical extent of 
the growth. The extension of the 
tumor should be outlined in detail 
.at clinical examination and at lapa-
rotomy. Excision of the carcinoma 
should be performed to the greatest 
possible extent. Every effort should 
be made to keep the capsule intact. 
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In cases of serous and endome-
trioid carcinoma fixed to surround-
ing tissue by firm adhesions, it may 
be appropriate to restrict the opera-
tion to an explorative laparotomy 
and to operate on the patient again 
10 to 14 days after completion of 
radiation. 
Intraperitoneal application of col-
loidal radioactive sources following 
surgery seems to decrease the risk 
of peritoneal implements and is su-
perior to radiomimetic substances 
in the palliation treatment of as-
cites. Removal of the primary ma-
lignancy is occasionally followed by 
regression of disseminated metas-
tases. 
Radiotherapy with adequate 
doses should be administered to all 
cases of true ovarian carcinoma 
limited to the pelvis. Endometrioid 
carcinomas may respond better to 
radiation than serous tumours. In 
advanced cases of carcinoma with 
unresectable metastases above the 
pelvis, chemotherapy should be ad-
ministered either as the only treat-
ment or in combination with radia-
tion. Chemotherapy should be 
applied in doses that lead to de-
pression of the bone marrow. Re-
cent experience has shown that 
many times the palliative effect 
from chemotherapy is superior to 
that from radiotherapy. 
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